Radiopharm Theranostics Limited (ASX:RAD)
Australia · Delayed Price · Currency is AUD 0.0140
0.00 (0.00%)
Jul 31, 2026, 4:11 PM AEST
Radiopharm Theranostics Balance Sheet
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Cash & Equivalents | 34.52 | 29.12 | 18.58 | 11.7 | 26.98 | 0.03 |
Cash & Short-Term Investments | 34.52 | 29.12 | 18.58 | 11.7 | 26.98 | 0.03 |
Cash Growth | 18.54% | 56.75% | 58.77% | -56.64% | 99486.97% | - |
Accounts Receivable | 0.62 | - | - | 0.1 | 0.06 | - |
Other Receivables | 10.74 | 10.4 | 0.99 | 4.36 | 0 | 0.01 |
Receivables | 11.36 | 10.4 | 0.99 | 4.47 | 0.06 | 0.01 |
Other Current Assets | 0.17 | 0.34 | 3.29 | 0.13 | 0.23 | - |
Total Current Assets | 46.04 | 39.85 | 22.85 | 16.3 | 27.26 | 0.03 |
Property, Plant & Equipment | 0.05 | 0.05 | 0.06 | 0.07 | 0 | - |
Other Intangible Assets | 45.08 | 46.57 | 49.09 | 58.54 | 56.08 | - |
Other Long-Term Assets | - | - | 0.04 | 0.04 | 0.04 | - |
Total Assets | 91.17 | 86.48 | 72.04 | 74.95 | 83.38 | 0.03 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Accounts Payable | 8.36 | 6.35 | 6.43 | 2.96 | 1.19 | 0.06 |
Accrued Expenses | 2.84 | 3.2 | 2.57 | 2.11 | 1.02 | 0.03 |
Short-Term Debt | - | - | - | - | - | 0.06 |
Current Unearned Revenue | 1.02 | 1.72 | - | - | - | - |
Other Current Liabilities | 3.08 | 3.66 | 8.57 | 8.16 | 5.66 | - |
Total Current Liabilities | 15.3 | 14.93 | 17.58 | 13.23 | 7.88 | 0.16 |
Other Long-Term Liabilities | 25.94 | 28.68 | 27.11 | 16.14 | 12.54 | - |
Total Liabilities | 41.23 | 43.61 | 44.68 | 29.37 | 20.42 | 0.16 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Common Stock | 209.94 | 176.56 | 100.68 | 97.23 | 86.76 | 0 |
Retained Earnings | -172.37 | -145.73 | -111.34 | -65.35 | -30.91 | -0.49 |
Comprehensive Income & Other | 14.22 | 13.97 | 38.78 | 12.51 | 7.11 | 0.36 |
Total Common Equity | 51.78 | 44.79 | 28.12 | 44.38 | 62.96 | -0.12 |
Minority Interest | -1.84 | -1.92 | -0.77 | 1.19 | - | - |
Shareholders' Equity | 49.94 | 42.87 | 27.35 | 45.58 | 62.96 | -0.12 |
Total Liabilities & Equity | 91.17 | 86.48 | 72.04 | 74.95 | 83.38 | 0.03 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
Total Debt | - | - | - | - | - | 0.06 |
Net Cash (Debt) | 34.52 | 29.12 | 18.58 | 11.7 | 26.98 | -0.03 |
Net Cash Growth | 18.54% | 56.75% | 58.77% | -56.64% | - | - |
Net Cash Per Share | 0.01 | 0.01 | 0.05 | 0.04 | 0.15 | - |
Filing Date Shares Outstanding | 3,544 | 2,365 | 2,173 | 339.31 | 255.43 | 100 |
Total Common Shares Outstanding | 3,544 | 2,365 | 460.37 | 339.31 | 255.43 | 100 |
Working Capital | 30.75 | 24.92 | 5.27 | 3.07 | 19.39 | -0.12 |
Book Value Per Share | 0.01 | 0.02 | 0.06 | 0.13 | 0.25 | -0.00 |
Tangible Book Value | 6.7 | -1.78 | -20.96 | -14.16 | 6.89 | -0.12 |
Tangible Book Value Per Share | 0.00 | -0.00 | -0.05 | -0.04 | 0.03 | -0.00 |